MA54460A - Formulations pharmaceutiques à base d'eau de composés de 1,2-dihydropyridine - Google Patents

Formulations pharmaceutiques à base d'eau de composés de 1,2-dihydropyridine

Info

Publication number
MA54460A
MA54460A MA054460A MA54460A MA54460A MA 54460 A MA54460 A MA 54460A MA 054460 A MA054460 A MA 054460A MA 54460 A MA54460 A MA 54460A MA 54460 A MA54460 A MA 54460A
Authority
MA
Morocco
Prior art keywords
water
pharmaceutical formulations
based pharmaceutical
dihydropyridine compounds
dihydropyridine
Prior art date
Application number
MA054460A
Other languages
English (en)
French (fr)
Inventor
Ganesh S P Bommareddy
Geoffrey S Hird
Anjali Joshi
James Mcshane
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MA54460A publication Critical patent/MA54460A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA054460A 2018-12-14 2019-12-16 Formulations pharmaceutiques à base d'eau de composés de 1,2-dihydropyridine MA54460A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862779620P 2018-12-14 2018-12-14

Publications (1)

Publication Number Publication Date
MA54460A true MA54460A (fr) 2021-10-20

Family

ID=69174604

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054460A MA54460A (fr) 2018-12-14 2019-12-16 Formulations pharmaceutiques à base d'eau de composés de 1,2-dihydropyridine

Country Status (11)

Country Link
US (1) US12303499B2 (https=)
EP (1) EP3893844A1 (https=)
JP (1) JP7177937B2 (https=)
KR (1) KR102912861B1 (https=)
CN (1) CN113226286B (https=)
AU (1) AU2019395288B2 (https=)
BR (1) BR112021010953A2 (https=)
CA (1) CA3122705A1 (https=)
MA (1) MA54460A (https=)
MX (1) MX2021006317A (https=)
WO (1) WO2020124090A1 (https=)

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356902A (en) 1992-11-06 1994-10-18 Eli Lilly And Company Decahydroisoquinoline compounds as excitatory amino acid receptor antagonists
IL109397A0 (en) 1993-04-28 1994-07-31 Schering Ag Quinoxalinedione derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
HU219777B (hu) 1993-07-02 2001-07-30 Gyógyszerkutató Intézet Kft. Optikailag aktív 1-(4-nitro-fenil)-4-metil-7,8-metiléndioxi-3,4-dihidro-5H-2,3-benzodiazepin és eljárás előállítására
HU223945B1 (hu) 1994-09-27 2005-03-29 Yamanouchi Pharmaceutical Co., Ltd. 1,2,3,4-Tetrahidro-kinoxalin-dion-származékok és ezeket tartalmazó gyógyszerkészítmények
US5935551A (en) 1995-11-15 1999-08-10 California Institute Of Technology Synthesis of zeolites by hydrothermal reaction of zeolite P1
DE19604920A1 (de) 1996-02-01 1997-08-07 Schering Ag Neue 2,3-Benzodiazepinderivate, deren Herstellung und Verwendung als Arzneimittel
US5891871A (en) 1996-03-21 1999-04-06 Cocensys, Inc. Substituted 2,3-benzodiazepin-4-ones and the use thereof
HU9600871D0 (en) 1996-04-04 1996-05-28 Gyogyszerkutato Intezet New 2,3-benzodiazepine derivatives
KR100375155B1 (ko) 1996-05-15 2003-08-19 화이자 인코포레이티드 신규한2,3-이치환된-4(3에이치)-퀴나졸리논
DE19643037A1 (de) 1996-10-18 1998-04-23 Boehringer Ingelheim Kg Neue Oxadiazole, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
SK113299A3 (en) 1997-02-28 2001-05-10 Pfizer Prod Inc Atropisomers of 3-aryl-4(3h)-quinazolinones and their use as ampa-receptor antagonists
GB9711753D0 (en) 1997-06-06 1997-08-06 Merck Sharp & Dohme Therapeutic agents
JP2002519373A (ja) 1998-07-02 2002-07-02 エーザイ株式会社 製薬組成物及びそれらの使用
DE19835918A1 (de) 1998-08-07 2000-02-10 Dresden Arzneimittel Neue antikonvulsiv wirkende 4-Amino-1-aryl-pyridin-2-one und Verfahren zu deren Herstellung
IL152848A0 (en) 2000-06-12 2003-06-24 Eisai Co Ltd 1,2-dihydropyridine derivatives, pharmaceutical compositions containing the same and methods for the production thereof
GB0129260D0 (en) 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
MY148809A (en) 2004-07-06 2013-05-31 Eisai R&D Man Co Ltd Crystals of 1,2-dihydropyridine compound and their production process
WO2007072869A1 (ja) * 2005-12-21 2007-06-28 Eisai R & D Management Co., Ltd. 1,2-ジヒドロピリジン化合物の非晶質体
US20100099714A1 (en) * 2007-03-05 2010-04-22 Eisai R&D Management Co., Ltd. AMPA and NMDA Receptor Antagonists for Neurodegenerative Diseases
JP2015227288A (ja) 2012-08-31 2015-12-17 エーザイ・アール・アンド・ディー・マネジメント株式会社 けいれん重積発作の治療用医薬組成物
CN104644592A (zh) * 2013-11-25 2015-05-27 天津市汉康医药生物技术有限公司 一种吡仑帕奈药物组合物及其制备方法
CN104706604A (zh) * 2013-12-12 2015-06-17 北京星昊医药股份有限公司 一种吡仑帕奈冻干口崩片及其制备方法
EP4059522A1 (en) * 2015-02-06 2022-09-21 Marinus Pharmaceuticals, Inc. Intravenous ganaxolone formulations and their use in treating status epilepticus and other seizure disorders
CN106389367B (zh) 2016-11-16 2020-12-18 杭州朱养心药业有限公司 吡仑帕奈包衣片剂药物组合物
WO2018169798A1 (en) * 2017-03-11 2018-09-20 The Regents Of The University Of California Mitigation of cns disorders by combination therapy using neurosteroids, and ampa blockers

Also Published As

Publication number Publication date
AU2019395288B2 (en) 2025-04-03
CA3122705A1 (en) 2020-06-18
JP2022510947A (ja) 2022-01-28
BR112021010953A2 (pt) 2021-08-24
US20220023275A1 (en) 2022-01-27
CN113226286A (zh) 2021-08-06
KR102912861B1 (ko) 2026-01-15
KR20210107644A (ko) 2021-09-01
AU2019395288A1 (en) 2021-09-23
US12303499B2 (en) 2025-05-20
MX2021006317A (es) 2021-08-11
CN113226286B (zh) 2024-08-20
EP3893844A1 (en) 2021-10-20
WO2020124090A1 (en) 2020-06-18
JP7177937B2 (ja) 2022-11-24

Similar Documents

Publication Publication Date Title
MA52421A (fr) Composés pharmaceutiques
EP3442973A4 (en) INNOVATIVE COMPOUNDS AS AUTOTAXIN INHIBITORS AND PHARMACEUTICAL COMPOSITIONS THEREFOR
IL283134A (en) Alcohol-resistant drug formulations
EP3548000A4 (en) PHARMACEUTICAL COMPOSITIONS OF ATROPINE
EP3843704A4 (en) EMULSION FORMULATIONS OF MULTIKINAS INHIBITORS
EP3328843A4 (en) 1,3,4-OXADIAZOLSULFONAMID DERIVATIVE COMPOUNDS AS A HISTONDEACETYLASE INHIBITOR AND PHARMACEUTICAL COMPOSITION THEREWITH
MA46466A (fr) Formulations pharmaceutiques de protéines à viscosité réduite
MX378806B (es) Inhibidores de la arginasa y sus aplicaciones terapéuticas.
EP3256149A4 (en) FORMULATION FOR ORAL ADMINISTRATION OF ACTIVE SUBSTANCES
MX2020011478A (es) Formas solidas de 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il) -1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida y sus composiciones farmaceuticas y usos.
EP3405183A4 (en) ADAMATE DERIVATIVES FOR TREATING A FILOVIRUS INFECTION
MA49393A (fr) Poly(phosphoesters) destinés à l'administration d'acides nucléiques
MA55015A (fr) Formulations pharmaceutiques
MA50356A (fr) Composés bicycliques destinés à être utilisés en tant qu'inhibiteurs de la kinase rip1
MA50250A (fr) Compositions de tétrahydroimidazo quinoléine utilisées en tant qu'inhibiteurs de cbp/p300
EP3399979A4 (en) FORMULATIONS OF 2- (4-CHLOROPHENYL) -N - ((2- (2,6-DIOXOPIPER-IDIN-3-YL) -1-OX-O-SO-ISOLIN-5-YL) METHYL) -2,2-DIFLUOROETAMIDE
EP3917926A4 (en) IMIDAZOCHINOLINE AMINE DERIVATIVES, PHARMACEUTICAL COMPOSITION, USE THEREOF
EP3880671A4 (en) NOVEL COMPOUND AS A PROTEIN KINAS INHIBITOR AND PHARMACEUTICAL COMPOSITION THEREOF
EP3897593A4 (en) CANNABINOID FORMULATIONS AND PHARMACEUTICAL COMPOSITIONS
MA40781A (fr) Composition pharmaceutique d'isotrétinoïne à faible dosage destinée à la voie orale
EP4015001A4 (en) Oral pharmaceutical composition
EP3452441A4 (en) ALPHA-TRUXILLINIC DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS FROM THEREOF
EP3677652A4 (en) WATER BASED INK COMPOSITION
EP3976025A4 (en) PSMA IMAGING AGENT FORMULATIONS
EP3582759A4 (en) BIOEQUIVALENT PHARMACEUTICAL COMPOSITION OF PRE-ORDIOXETINE HYDROBROMIDE